| Record ID | ia:badpharmahowdrug0000gold_t4y1 |
| Source | Internet Archive |
| Download MARC XML | https://archive.org/download/badpharmahowdrug0000gold_t4y1/badpharmahowdrug0000gold_t4y1_marc.xml |
| Download MARC binary | https://www.archive.org/download/badpharmahowdrug0000gold_t4y1/badpharmahowdrug0000gold_t4y1_meta.mrc |
LEADER: 01344cam a2200337 i 4500
001 2012038902
003 DLC
005 20150207080524.0
008 121019s2013 nyua b 001 0 eng
010 $a 2012038902
020 $a9780865478008 (hbk. : alk. paper)
020 $a0865478007 (hbk. : alk. paper)
040 $aDLC$beng$cDLC$erda$dDLC
042 $apcc
050 00 $aRM301.27$b.G65 2013
082 00 $a615.1072/4$223
100 1 $aGoldacre, Ben.
245 10 $aBad pharma :$bhow drug companies mislead doctors and harm patients /$cBen Goldacre.
250 $aFirst American edition.
264 1 $aNew York :$bFaber and Faber, Inc., an affiliate of Farrar, Straus and Giroux,$c2013.
300 $axvii, 426 pages :$billustrations ;$c22 cm
336 $atext$2rdacontent
337 $aunmediated$2rdamedia
338 $avolume$2rdacarrier
504 $aIncludes bibliographical references (pages 371-405) and index.
505 0 $aIntro -- Missing data -- Where do new drugs come from? -- Bad regulators -- Bad trials -- Bigger, simpler trials -- Marketing -- Afterword: better data.
650 0 $aDrugs$xTesting.
650 0 $aDrugs$xTesting$xMoral and ethical aspects.
650 0 $aClinical trials$xMoral and ethical aspects.
650 0 $aPharmaceutical industry$xMoral and ethical aspects.
650 0 $aDrugs$xQuality control.